Benefits and risks of skin cancer screening

Oncology Research and Treatment

Volumn 37, Issue , 2014, Pages 38-47

  Breitbart, Eckhard W ^a,b   Choudhury, Kohelia ^a   Anders, Markus P ^a   Volkmer, Beate ^a,b   Greinert, Rüdiger ^a,b   Katalinic, Alexander ^c   Tacke, Jürgen ^d   Keilholz, Ulrich ^e  

^a Association of Dermatological Prevention   (Germany)

^b Center of Dermatology   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d Dermatologist   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; DISEASE COURSE; EARLY DIAGNOSIS; GERMANY; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; MELANOMA; NON MELANOMA SKIN CANCER; PROGRAM EFFECTIVENESS; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; SKIN BIOPSY; SKIN CANCER; SKIN CARCINOMA; SKIN EXAMINATION; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; FEMALE; INCIDENCE; INFORMED CONSENT; MALE; MORTALITY; RISK ASSESSMENT; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; FEMALE; GERMANY; HUMANS; INCIDENCE; INFORMED CONSENT; MALE; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84927651785     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000364887     Document Type: Article

References (60)

1. Wilson J, Jungner G. Principles and Practice of Screening for Disease. Geneva, World Health Organization, 1968
2. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, Katalinic A. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012;66:201-211
3. Linos E, Swetter S, Cockburn M, Colditz G, Clarke C. Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666-1674
4. Stang A, Stausberg J, Boedeker W, Kerek-Bodden H, Jöckel KH. Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol 2007;22:65-72
5. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute, 2013/2014
6. Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, Bray F. International trends in the incidence of malignant melanoma 1953-2008 -are recent generations at higher or lower risk?. Int J Cancer 2013;132:385-400
7. American Cancer Society: Skin Cancer Facts. Atlanta, GA, ACS, 2013/2014
8. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010; 127:2893-2917
9. Rigel DS, Carucci JA. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin 2000;50:215-236
10. Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT. Screening for skin cancer. Am J Prev Med 2001;20:47-58
11. American Cancer Society: Melanoma Skin Cancer. Atlanta, GA, ACS, 2013/2014
12. Tingenhög G, Carlsson P, Synnerstad I, Rosdahl I. Societal cost of skin cancer in Sweden in 2005. Acta Derm Venereol 2008;88:467-473
13. Lucas RM, McMichael AJ, Armstrong BK, Smith WT. Estimating the global disease burden due to ultraviolet radiation exposure. Int J Epidemiol 2008;37:654-667
14. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27:3-9
15. De Vries E, van De Poll-Franse LV, Louwman WJ, De Gruijl FR, Coebergh JW. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 2005;152:481-488
16. El Ghissassi F, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens -part D. radiation. Lancet Oncol 2009;10:751-752
17. Association of Population-Based Cancer Registries in Germany: GEKID Atlas, 2013/2014. www. gekid.de.
18. Hillhouse J, Turrisi R. Skin cancer risk behaviors: a conceptual framework for complex behavioral change. Arch Dermatol 2005;141:1028-1031
19. Joel Hillhouse GC, Thompson JK, Jacobsen PB, Hillhouse J. Investigating the role of appearancebased factors in predicting sunbathing and tanning salon use. J Behav Med 2009;32:532-544
20. Roberts DJ, Hornung CA, Polk HC Jr. Another duel in the sun: weighing the balances between sun protection, tanning beds, and malignant melanoma. Clin Pediatr (Phila) 2009;48:614-622
21. Melia J, Pendry L, Eiser JR, Harland C, Moss S. Evaluation of primary prevention initiatives for skin cancer: a review from a U.K. perspective. Br J Dermatol 2000;143:701-708
22. Katalinic A, Waldmann A, Weinstock MA, Geller AC, Eisemann N, Greinert R, Volkmer B, Breitbart E. Does skin cancer screening save lives?. An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012;118:5395-5402
23. Federal Joint Committee: Abschlussbericht zur Phase III (Pilotphase) des Projektes Weiterentwicklung Der Hautkrebsfrüherkennung im Rahmen Der gesetzlichen Krebsfrüherkennungsuntersuchung (KFU) als Vorbereitung für die flächendeckende Einführung, 2004
24. Waldmann A, Nolte S, Geller AC, Katalinic A, Weinstock MA, Volkmer B, Greinert R, Breitbart EW. Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations. Arch Dermatol 2012;148:903-910
25. Geller A, Sober A, Zhang Z, Brooks D, Miller D, Halpern A, Gilchrest B. Strategies for improving melanoma education and screening for men age ≤50 years -findings from the American Academy of Dermatology National Skin Cancer Screening Program. Cancer 2002;95:1554-1561
26. Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006;54:105-114
27. Paoli J, Danielsson M, Wennberg AM. Results of the Euromelanoma Day screening campaign in Sweden 2008. J Eur Acad Dermatol Venereol 2009;23:1304-1310
28. Geller A, Swetter S, Brooks K, Demierre M-F, Yaroch A. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol 2007;57:555-572
29. Schmitt J, Seidler A, Heinisch G, Sebastian G. Effectiveness of skin cancer screening for individuals age 14 to 34 years. J Dtsch Dermatol Ges 2011;9:608-616
30. Hense H, Katalinic A, Lebeau A, Müller-Schimpfle M, Skaane P, Wallwiener D. Verfahren zur Bewertung Der Wirksamkeit des deutschen Mammographie-Screening-Programms auf die Senkung Der Sterblichkeit durch Brustkrebs. Berlin, Kooperationsgemeinschaft Mammographie, 2011, 2014
31. Waldmann A, Nolte S, Weinstock MA, Breitbart EW, Eisemann N, Geller AC, Greinert R, Volkmer B, Katalinic A. Skin cancer screening participation and impact on melanoma incidence in Germany -an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012;106:970-974
32. Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, Breitbart EW, Katalinic A. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol 2014;134:43-50
33. Eisemann N, Waldmann A, Katalinic A. Incidence of melanoma and changes in stage-specific incidence after implementation of skin cancer screening in Schleswig-Holstein. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014;57:77-83
34. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685-1692
35. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 2006;185:482-486
36. Choudhury K, Volkmer B, Greinert R, Christophers E, Breitbart EW. Effectiveness of skin cancer screening programmes. Br J Dermatol 2012;167 (suppl 2):94-98
37. Federal Joint Committee: Richtlinie des Gemeinsamen Bundesausschusses über die Früherkennung von Krebserkrankungen (Krebsfrüherkennungs-Richtlinie/KFE-RL). Bundesanzeiger 2009;Nr. 148a.
38. Fischer M, Kerek-Bodden H, Mukhtar AM, von Stillfried D. Plädoyer für ein kontinuierliches Fortbildungsprogramm. Dtsch Arztebl 2010;107
39. National Association of Statutory Health Insurance Physicians: Erste Bilanz zum Hautkrebsscreening liegt vor. Berlin, KBV, 2010, 2014
40. Australian Cancer Network and New Zealand Guidelines Group: Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. www.nhmrc.gov.au/-files-nhmrc/publications/attachments/cp111.pdf .
41. Bigby M. Why the evidence for skin cancer screening is insufficient: lessons from prostate cancer screening. Arch Dermatol 2010;146:322-324
42. Melanoma Research Foundation: Detection and Screening. www.melanoma.org/understand-melanoma/diagnosing-melanoma/detection-screening
43. Cancer Care Ontario (CCO): Screening for Skin Cancer. www.cancercare.on.ca/common/pages/User File.aspx?fileId=13942
44. Memorial Sloan Kettering Cancer Center: Skin Cancer Screening Guidelines. www.mskcc.org/cancer-care/adult/skin/screening-guidelines-skin
45. Techniker Krankenkasse (TK): Hautkrebs-Screening. www.tk.de/tk/tk-vorsorgeleistungen/frueherkennung-fuer-erwachsene/hautkrebs/35626
46. Robert Koch-Institut: Krebs in Deutschland 2009/2010. www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBE DownloadsB/KID2013.html
47. Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 2010;126:450-458
48. Fritschi L, Dye SA, Katris P. Validity of melanoma diagnosis in a community-based screening program. Am J Epidemiol 2006;164:385-390
49. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159-165
50. BARMER GEK: Barmer GEK Arztreport 2014. Schwerpunkt Hautkrebs. St. Augustin, Asgard, 2014. www.presse.barmer-gek.de/barmer/web/Portale/Presseportal/Subportal/Presseinformationen/Archiv/2014/140204-Arztreport/PDF-Arztreport-2014, property=Data.pdf
51. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996;27:528-531
52. National Cancer Institute: PDQ® Skin Cancer Screening. www.cancer.gov/cancertopics/pdq/screening/skin/HealthProfessional. Last update 26 September 2013
53. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150: 194-198
54. Curiel-Lewandrowski C, Chen SC, Swetter SM. Screening and prevention measures for melanoma: is there a survival advantage?. Curr Oncol Rep 2012;14:458-467
55. Weinstock MA. Reducing death from melanoma and standards of evidence. J Invest Dermatol 2012; 132:1311-1312
56. Aitken JF, Elwood JM, Lowe JB, Firman DW, Balanda KP, Ring IT. A randomised trial of population screening for melanoma. J Med Screen 2002;9:33-37
57. Schneider JS, Moore DH, Mendelsohn ML. Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol 2008;58:741-749
58. Swetter SM, Pollitt RA, Johnson TM, Brooks DR, Geller AC. Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. Cancer 2012;118:3725-3734
59. Chan V, Thompson I, Whitney D, Switzer M, Anderson AD, Smits S. Migration and melanoma incidence rates among Washington state counties. Melanoma Res 2013;23:312-320
60. Gemeinsamer Bundesausschuss (G-BA): Hautkrebsscreening. Zusammenfassende Dokumentation des Unterausschusses Prävention des Gemeinsamen Bundesauschusses. www.g-ba.de/downloads/40-268-580/2008-03-31-Abschluss-Hautkrebsscreening.pdf